1048 related articles for article (PubMed ID: 30628719)
21. [The roles of holothurian glycosaminoglycan combined with cisplatin on proliferation and chemotherapeutic response in A549 human lung adenocarcinoma cell].
Jin Q; Zhu XH; Lin CZ; Zhang H; Cao YW; Ding XQ; Lyu ZH
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):252-257. PubMed ID: 29730910
[No Abstract] [Full Text] [Related]
22. Knockdown of circ‑PVT1 inhibits the progression of lung adenocarcinoma and enhances the sensitivity to cisplatin via the miR‑429/FOXK1 signaling axis.
Cao L; Zhou X; Ding X; Gao D
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328193
[TBL] [Abstract][Full Text] [Related]
23. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
[TBL] [Abstract][Full Text] [Related]
24. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
25. Reversal effect of adenovirus-mediated human interleukin 24 transfection on the cisplatin resistance of A549/DDP lung cancer cells.
Xu M; Tang X; Guo J; Sun W; Tang F
Oncol Rep; 2017 Nov; 38(5):2843-2851. PubMed ID: 29048638
[TBL] [Abstract][Full Text] [Related]
26. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
Chen P; Li J; Jiang HG; Lan T; Chen YC
Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
[TBL] [Abstract][Full Text] [Related]
27. Increased sensitivity of human lung adenocarcinoma cells to cisplatin associated with downregulated contactin-1.
Zhang R; Yao W; Qian P; Li Y; Jiang C; Ao Z; Qian G; Wang C; Wu G; Li J; Ji F; Xu J
Biomed Pharmacother; 2015 Apr; 71():172-84. PubMed ID: 25960233
[TBL] [Abstract][Full Text] [Related]
28. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of replication protein A 3 induces protective autophagy and enhances cisplatin sensitivity in lung adenocarcinoma by inhibiting AKT/mTOR signaling via binding to cyclin-dependent kinases regulatory subunit 2.
Chen L; Hu K; Liu Y; Liu L; Tang J; Qin X
Drug Dev Res; 2022 Nov; 83(7):1589-1599. PubMed ID: 35903032
[TBL] [Abstract][Full Text] [Related]
30. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
Teng X; Wang SY; Shi YQ; Fan XF; Liu S; Xing Y; Guo YY; Dong M
Anticancer Drugs; 2021 Oct; 32(9):939-949. PubMed ID: 34001704
[TBL] [Abstract][Full Text] [Related]
31. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
Zhang B; Liu ZM; Hao FG; Wang M
Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
[TBL] [Abstract][Full Text] [Related]
32. An inverse interaction between
Zhang Y; Yuan Y; Li Y; Zhang P; Chen P; Sun S
Epigenetics; 2019 Oct; 14(10):949-960. PubMed ID: 31144606
[No Abstract] [Full Text] [Related]
33. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
Xie C; Pan Y; Hao F; Gao Y; Liu Z; Zhang X; Xie L; Jiang G; Li Q; Wang E
APMIS; 2014 Dec; 122(12):1251-8. PubMed ID: 25131138
[TBL] [Abstract][Full Text] [Related]
34. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
36. miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Huang T; Ren K; Ding G; Yang L; Wen Y; Peng B; Wang G; Wang Z
Oncol Rep; 2020 Jun; 43(6):1906-1914. PubMed ID: 32186774
[TBL] [Abstract][Full Text] [Related]
37. Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway.
Wu T; Wang MC; Jing L; Liu ZY; Guo H; Liu Y; Bai YY; Cheng YZ; Nan KJ; Liang X
Drug Des Devel Ther; 2015; 9():6421-31. PubMed ID: 26715839
[TBL] [Abstract][Full Text] [Related]
38. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
[TBL] [Abstract][Full Text] [Related]
40. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
Liu B; Wang R; Liu H
Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
